Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | UBE2M | P61081 | 1/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7978594 | 0.88 | UBE2M (0.44) | EPHX1UBE2MDCUN1D1EPHX2HTR2C | |
| SCHEMBL6710676 | 0.68 | SCN9A (0.45) | MEN1KMT2A | |
| SCHEMBL23390173 | 0.67 | HTR2C (0.59) | EPHX1EPHX2HTR2CMEN1NPC1 | |
| SCHEMBL6499006 | 0.66 | EPHX2 (0.36) | EPHX1EPHX2MEN1NPC1TSHR | |
| SCHEMBL6486203 | 0.66 | EPHX2 (0.47) | UBE2MDCUN1D1EPHX2KMT2AACHE | |
| SCHEMBL5870950 | 0.64 | OPRD1 (0.41) | KMT2AL3MBTL1 | |
| SCHEMBL17488206 | 0.63 | HTR2C (0.68) | EPHX1EPHX2HTR2CMEN1NPC1 | |
| SCHEMBL23390079 | 0.63 | HTR2C (0.68) | EPHX1EPHX2HTR2CMEN1NPC1 | |
| SCHEMBL7492223 | 0.63 | HTT (0.39) | MEN1TSHRKMT2A | |
| SCHEMBL5871129 | 0.63 | RPLP1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946477-B2 | 3-Substituted piperidines comprising urea functionality, and methods of use thereof | SEPRACOR INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20030114436-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | AQUILA BRIAN M (US) | 2003-06-19 | — | — | US | disclosed |
| US-6476050-B2 | ANALGESICS; LIGANDS FOR VARIOUS CELLULAR RECEPTORS, INCLUDING OPIOID RECEPTORS, OTHER G-PROTEIN-COUPLED RECEPTORS AND ION CHANNELS | SEPRACOR, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20010056090-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | SEPRACOR INC. | 2001-12-27 | — | — | US | disclosed |
| WO-2001068604-A2 | 3-SUBSTITUTED PIPERIDINES COMPRISING UREA FUNCTIONALITY, AND METHODS OF USE THEREOF | SEPRACOR, INC. (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056090-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | OPRM1, OPRL1, OPRK1 | EPHX1 1270/4885UBE2M 663/4885DCUN1D1 3813/4885 |
| US-20030114436-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | OPRM1, OPRL1, OPRK1 | EPHX1 1270/4885UBE2M 663/4885DCUN1D1 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.